# EDGAR Filing Document

**Accession Number:** 0002101782
**File Stem:** 0001193805-25-001763
**Filing Date:** 2025-12
**Character Count:** 7324
**Document Hash:** b52f646fcabbdf471df1b48b958b2d7d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193805-25-001763.hdr.sgml**: 20251219

**ACCESSION NUMBER**: 0001193805-25-001763

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20251212

**FILED AS OF DATE**: 20251219

**DATE AS OF CHANGE**: 20251219

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Roberts Joseph
- **CENTRAL INDEX KEY:** 0002101782

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38942
- **FILM NUMBER:** 251588573

**MAIL ADDRESS:**
- **STREET 1:** 10285 SCIENCE CENTER DRIVE
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Arcturus Therapeutics Holdings Inc.
- **CENTRAL INDEX KEY:** 0001768224
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 10285 SCIENCE CENTER DRIVE
- **CITY:** SAN DIEGO
- **STATE:** CA
- **BUSINESS PHONE:** 8589002660

**MAIL ADDRESS:**
- **STREET 1:** 10285 SCIENCE CENTER DRIVE
- **CITY:** SAN DIEGO
- **STATE:** CA

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Roberts Joseph<br><sub>(Last) (First) (Middle)</sub><br>C/O ARCTURUS THERAPEUTICS HOLDINGS INC.<br>10285 SCIENCE CENTER DRIVE<br><sub>(Street)</sub><br>SAN DIEGO, CA 92121<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>Arcturus Therapeutics Holdings Inc. [ ARCT ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2025-12-12 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [ ] 10% Owner<br>[X] Officer (give title below)   [ ] Other (specify below)<br>_Controller_ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |
| Common Stock | 2001 | D |  |
| Common Stock | 200 | I | Spouse |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Stock Option (Right to Buy) | <sup>(1)</sup> | 2028-08-24 | Common Stock | 5000 | $8.00 | D |  |
| Stock Option (Right to Buy) | <sup>(2)</sup> | 2030-02-18 | Common Stock | 5000 | $14.12 | D |  |
| Stock Option (Right to Buy) | <sup>(3)</sup> | 2030-12-18 | Common Stock | 2808 | $99.29 | D |  |
| Stock Option (Right to Buy) | <sup>(4)</sup> | 2030-12-18 | Common Stock | 6492 | $99.29 | D |  |
| Stock Option (Right to Buy) | <sup>(5)</sup> | 2031-12-10 | Common Stock | 7000 | $34.57 | D |  |
| Stock Option (Right to Buy) | <sup>(6)</sup> | 2032-12-09 | Common Stock | 7000 | $16.92 | D |  |
| Stock Option (Right to Buy) | <sup>(7)</sup> | 2033-12-15 | Common Stock | 7500 | $28.88 | D |  |
| Stock Option (Right to Buy) | <sup>(8)</sup> | 2034-02-22 | Common Stock | 1000 | $37.44 | D |  |
| Stock Option (Right to Buy) | <sup>(9)</sup> | 2034-12-16 | Common Stock | 9000 | $16.24 | D |  |

---

### Footnotes:

(1) The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining vesting 1/36th per month over the following three years. The option was granted on August 24, 2018.

(2) The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining vesting 1/36th per month over the following three years. The option was granted on February 18, 2020.

(3) The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining vesting 1/36th per month over the following three years. The option was granted on December 18, 2020.

(4) The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining vesting 1/36th per month over the following three years. The option was granted on December 18, 2020.

(5) The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining vesting 1/36th per month over the following three years. The option was granted on December 10, 2021.

(6) The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining vesting 1/36th per month over the following three years. The option was granted on December 9, 2022.

(7) The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining vesting 1/36th per month over the following three years. The option was granted on December 15, 2023.

(8) The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining vesting 1/36th per month over the following three years. The option was granted on February 22, 2024.

(9) The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining vesting 1/36th per month over the following three years. The option was granted on December 16, 2024.

**Signature:** /s/ Grant Levine, attorney-in-fact  
**Date:** 2025-12-19

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**